Breast cancer is a highly prevalent and molecularly heterogeneous malignancy, where therapeutic resistance and off-target toxicity remain major challenges. Here, we introduce BreastCAR, a multi-target quantitative structure-activity relationship framework trained on ChEMBL bioactivity data covering 53 cancer-relevant t...
Stalin Arulsamy, D. Ramesh, Vanktesh Kumar et al.· Molecular Informatics· 0 citations
Chalcones represent a tractable, polypharmacological scaffold with target engagement validated across 145 human proteins, and hit-rate patterns provide reliable evidence even after accounting for reporting bias, although translational claims require independent experimental validation.
S. Arulsamy, Kiruthiga Natarajan, S. K. Krishnan et al.· Current Drug Targets· 0 citations
The experimental data suggest that Murrayanine delivered as SLNs is a promising preclinical candidate for breast cancer treatment, and an integrated use of computational and experimental approaches highlights the ability of natural product drug discovery to address breast cancer.
Yue Di, Xin-Cheng Hu, Jin-Dong Dai et al.· Journal of Steroid Biochemis...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.